BidaskClub lowered shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a hold rating in a research note issued to investors on Wednesday, January 10th.
Several other equities analysts have also recently issued reports on the company. Barclays started coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an overweight rating and a $20.00 price target on the stock. Zacks Investment Research raised Sangamo Therapeutics from a hold rating to a buy rating and set a $14.00 target price on the stock in a research note on Wednesday, November 15th. Piper Jaffray Companies raised Sangamo Therapeutics from a neutral rating to an overweight rating and set a $19.00 price target on the stock in a research report on Wednesday, November 15th. Wedbush reaffirmed a hold rating and set a $6.00 price target on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Finally, Jefferies Group reaffirmed a buy rating and set a $18.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, September 14th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of Buy and a consensus price target of $18.83.
Shares of Sangamo Therapeutics (NASDAQ SGMO) traded up $0.35 during mid-day trading on Wednesday, hitting $21.20. The stock had a trading volume of 1,194,386 shares, compared to its average volume of 1,260,000. The company has a market capitalization of $1,790.00, a PE ratio of -30.72 and a beta of 3.15. Sangamo Therapeutics has a 12 month low of $3.50 and a 12 month high of $21.90. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.
In related news, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total value of $258,900.00. Following the sale, the vice president now owns 13,015 shares of the company’s stock, valued at approximately $224,638.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Saira Ramasastry sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $73,350. The disclosure for this sale can be found here. In the last three months, insiders sold 58,433 shares of company stock worth $979,696. 5.50% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of the business. Chicago Equity Partners LLC bought a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $192,000. Fox Run Management L.L.C. grew its stake in Sangamo Therapeutics by 353.8% in the fourth quarter. Fox Run Management L.L.C. now owns 63,075 shares of the biopharmaceutical company’s stock valued at $1,034,000 after purchasing an additional 49,175 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Sangamo Therapeutics by 13.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 433,717 shares of the biopharmaceutical company’s stock valued at $7,113,000 after purchasing an additional 51,801 shares in the last quarter. Neuberger Berman Group LLC bought a new position in Sangamo Therapeutics in the third quarter valued at approximately $315,000. Finally, Cubist Systematic Strategies LLC grew its stake in Sangamo Therapeutics by 143.9% in the third quarter. Cubist Systematic Strategies LLC now owns 19,942 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 11,766 shares in the last quarter. Hedge funds and other institutional investors own 64.09% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Sangamo Therapeutics (NASDAQ:SGMO) Downgraded by BidaskClub to Hold” was published by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/bidaskclub-lowers-sangamo-therapeutics-sgmo-to-hold/1822788.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.